|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated whether salivary levels of MMP-9 and MPO corresponded to plasma levels in patients with coronary artery disease (CAD), both at rest and after acute physical exercise.
|
30726210 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple lines of evidence suggest an association between MPO and cardiovascular disease (CVD) including coronary artery disease, congestive heart failure, arterial hypertension, pulmonary arterial hypertension, peripheral arterial disease, myocardial ischemia/reperfusion-related injury, stroke, cardiac arrhythmia and venous thrombosis.
|
30797769 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data implicate MPO in atherosclerotic plaque instability and suggest that non-invasive imaging and pharmacological inhibition of plaque MPO activity hold promise for clinical translation in the management of high-risk coronary artery disease.
|
30219874 |
2018 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Design and methods We investigated whether the circulating neutrophil extracellular traps markers, double-stranded DNA and myeloperoxidase-DNA were associated with clinical outcome and hypercoagulability in patients with stable coronary artery disease.
|
29473463 |
2018 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
|
29618370 |
2018 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease.
|
29505607 |
2018 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase emerges as a crucial mediator of postischemic myocardial remodeling and may evolve as a novel pharmacological target for secondary disease prevention after myocardial ischemia.
|
28404615 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.
|
28668952 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PRISMA-combined Myeloperoxidase -463G/A gene polymorphism and coronary artery disease: A meta-analysis of 4744 subjects.
|
28328864 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myeloperoxidase polymorphism and coronary artery disease risk: A meta-analysis.
|
28682877 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture.
|
27884085 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background Myeloperoxidase has shown potential as a marker for prognosis of coronary artery disease, but presently little is known about preanalytical handling of samples for quantifying myeloperoxidase.
|
27422133 |
2017 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease.
|
26323267 |
2016 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MPO concentrations but not genetic variants at the MPO locus are independently associated with risk for total and cardiovascular mortality in coronary artery disease patients.
|
24746542 |
2014 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The myeloperoxidase -463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls.
|
24036021 |
2013 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myeloperoxidase G-463A polymorphism and susceptibility to coronary artery disease: a meta-analysis.
|
23583798 |
2013 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.
|
20568015 |
2011 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease.
|
19651119 |
2010 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase (MPO) is an inflammatory enzyme produced by activated leukocytes that predicts risk of coronary heart disease.
|
18514165 |
2008 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vivo, chemical deacetylation of GXM significantly reduced its ability to interfere with neutrophil recruitment in a model of myocardial ischemia (65% reduction vs a nonsignificant reduction in tissue myeloperoxidase, respectively).
|
15585878 |
2004 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians.
|
11479475 |
2001 |